As resistance to antibiotics continues to grow, there is a well-recognized misalignment between the clinical need for new antibiotics and the incentives for their development. The returns from investment in antibiotics research and development (R&D) are perceived as too small. Partly as a result, the number of large multinational companies researching antibiotics has fallen drastically in the past 20 years and few high-quality antibiotics have been developed.
Kevin Outterson, Ella Jaczynska & Jorge Mestre-Ferrandiz,
Business Model Options for Antibiotics: Learning from Other Industries,
Available at: https://scholarship.law.bu.edu/faculty_scholarship/119